Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection

Clinical Pharmacology and Therapeutics

Volumn 71, Issue 3, 2002, Pages 122-130

  Grub, Sibylle ^a,b,c,d   DeLora, Patricia ^a,b,c,d   Lüdin, Eric ^a,b,c,d   Duff, Frank ^a,b,c,d   Fletcher, Courtney V ^a,b,c,d   Brundage, Richard C ^a,b,c,d   Kline, Mark W ^a,b,c,d   Calles, Nancy R ^a,b,c,d   Schwarzwald, Heidi ^a,b,c,d   Jorga, Karin ^a,b,c,d  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b HOFFMANN LA ROCHE INC   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATIN; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR;

ADOLESCENT; AGE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; CROSSOVER PROCEDURE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG EXPOSURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; METABOLIC INHIBITION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; STEADY STATE; VIRUS LOAD;

ADOLESCENT; AREA UNDER CURVE; BLOOD PROTEINS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; NELFINAVIR; RANDOMIZED CONTROLLED TRIALS; SAQUINAVIR;

EID: 0036215227     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.121423     Document Type: Article

References (21)

1. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy
2. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate
3. Indinavir pharmacokinetics and pharmacodynamics in children with human immunodeficiency virus infection
4. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection
5. US approved labeling for Kaletra®
6. Saquinavir soft-gel capsule formulation
7. Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits
8. Protease inhibitors in patients with HIV disease
9. Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection
10. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies
11. Evaluation of the ultrasensitive Roche Amplicor HIV-1 monitor assay for quantitation of human immunodeficiency virus type 1 RNA
12. Quantitative and cost comparison of ultra-sensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5
13. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients
14. US approved labeling for Fortovase®
15. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection
16. Nelfinavir mesylate (NFV) increases saquinavir-soft gel capsule (SQV-SGC) exposure in HIV positive patients